Coronavirus vaccine COVAXIN is India’s first indigenous inactivated vaccine for highly infectious and deadly disease COVID-19. Covaxin is developed by Bharat Biotech India (BBIL). Central Drugs Standard Control Organisation has given permission for human clinical trials for ‘Covaxin’. The first two phases of human trials for the vaccine, called Covaxin, are scheduled to start across the country in July.
The vaccine was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and National Institute of Virology. Covaxin is a vaccine candidate to developed by BBIL against the novel coronavirus (Covid-19) in collaboration with the Indian Council of Medical Research’s National Institute of Virology (NIV).
According to a release, human clinical trials Phase 1 and Phase 2 of the COVAXIN will commence from July, therefore, at present no confirm information is available as to when the vaccine will be available in the market for human use. A press release by the company, Bharat Biotech, it said results from these studies have been promising and show extensive safety and effective immune responses.
Bharat Biotech’s Chairman and Managing Director, Dr Krishna Ella says “We are proud to announce COVAXIN, India’s first indigenous vaccine against COVID-19. The collaboration with ICMR and NIV was instrumental in the development of this vaccine.
He added, “Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform,” he said. Expedited through the national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies.
The vaccine is Covaxin and has been locally developed in collaboration with India’s National Institute of Virology and Indian Council of Medical Research, according to Dr Krishna Ella, chairman of Bharat Biotech.